NeuroSense Therapeutics (NeuroSense Therapeutics) Net Change in Cash : $0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is NeuroSense Therapeutics Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

NeuroSense Therapeutics's Net Change in Cash for the three months ended in Dec. 2023 was $0.00 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.

NeuroSense Therapeutics Net Change in Cash Historical Data

The historical data trend for NeuroSense Therapeutics's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuroSense Therapeutics Net Change in Cash Chart

NeuroSense Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Net Change in Cash

0.81

-0.20

10.36

-7.52

-0.90

NeuroSense Therapeutics Quarterly Data
	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Change in Cash	Get a 7-Day Free Trial										-	-	-	-	-

NeuroSense Therapeutics Net Change in Cash Calculation

NeuroSense Therapeutics's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-8.452	+	3.646	+	3.895	+	0.008
	=	-0.90

NeuroSense Therapeutics's Net Change in Cash for the quarter that ended in Dec. 2023

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= 0 + 0 + 0 + 0

= 0.00

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeuroSense Therapeutics Net Change in Cash Related Terms
Thank you for viewing the detailed overview of NeuroSense Therapeutics's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

NeuroSense Therapeutics (NeuroSense Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuroSense Therapeutics Ltd (NAS:NRSN) » Definitions » Net Change in Cash

Comparable Companies

FNCH CELZ CYCN LIXT BTTX ALRN CUBT EMMA TTNP RASP OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX

Traded in Other Exchanges

N/A

Address

11 HaMenofim Street, Building B, Herzliya, ISR, 4676670

Website

https://www.neurosense-tx.com

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

NeuroSense Therapeutics (NeuroSense Therapeutics) Headlines

From GuruFocus

NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts
By PRNewswire • 01-09-2024

NeuroSense CEO Provides Q2 2023 Update
By PRNewswire • 07-06-2023

NeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial Readiness
By PRNewswire • 11-14-2023

NeuroSense to Participate in Upcoming ALS Conferences: European Network to Cure ALS & EverythingALS Digital Biomarkers Summit
By PRNewswire • 07-11-2023

NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial
By PRNewswire • 12-14-2023

NeuroSense Receives Approval in Germany to Enroll Patients in its Phase 2b ALS Trial
By PRNewswire PRNewswire • 02-08-2023

NeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023
By PRNewswire • 11-14-2023

NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement
By PRNewswire • 12-27-2023

NeuroSense Reports First Quarter 2023 Financial Results & Provides Business Update: Phase 2b ALS Trial Completes Enrollment, Topline Data Expected Q4 2023
By PRNewswire PRNewswire • 06-01-2023

NeuroSense CEO Recaps 2022 Achievements & Presents 2023 Catalysts
By PRNewswire PRNewswire • 02-13-2023